A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

NCT03449147 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1317

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Cough

Interventions

DRUG: Placebo
DRUG: Gefapixant 15 mg BID
DRUG: Gefapixant 45 mg BID

Sponsor

Merck Sharp & Dohme LLC